Pharma & Biotech Global Week in Review 3 June 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page:

Highlights this week included:

Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb)


Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech Director at EPO discusses European patent practice – Patent Docs)

Process of continuous improvement and pharmaceuticals (Profitability through Simplicity)

Africa: Nigeria (and Africa’s) drug problem – Africa’s capacity to manufacture drugs (Afro-IP)

Canada: Private Members’ bills seek amendments to Patent Act and Food and Drugs Act (Pharmacapsules @ Gowlings)

EU: ‘Public health and the preservation of economic competitiveness: the European supplementary protection certificate for medicinal products’ article available (The SPC Blog)

India: Interim injunction granted against Assistant Registrar of Trademarks: Glenmark Pharmaceuticals v Assistant Registrar of Trademarks (International Law Office)

India: IP management in Indian agricultural research (Spicy IP)

Lithuania: Popularity of medicinal product does not make trademarks customary – CITRAMON-FORTE STIROL v NEOCITRAMONAS (International Law Office)

US: Supreme Court, In re Bilski and the lingering question of Labcorp v Metabolite (Patent Docs)

US: CAFC: Declaratory judgment – personal jurisdiction over foreign patent holder: Autogenomics v Oxford Gene Tech (Patently-O)

US: Pharmasset sued for patent infringement over its development of pharmaceutical compositions through the use of the TET system: TET System Holding GmbH & Co KG v Pharmasset, Inc (Patent Docs)

US: Mylan’s Chief Officer to testify before Congress concerning patent settlements between brand and generic pharmaceutical companies and tactics that delay entry of high quality, affordable generic drugs (SmartBrief)


Actonel (Risedronate) – US: CAFC affirms validity, unpredictable nature of chemicals can defeat obviousness claim: P&G v Teva Pharma (Patent Baristas)

Actoplus MET (Pioglitazone hydrochloride, Metformin) US: Takeda files patent infringement suit against Teva following Para IV certification (Patent Docs)

Advair (Fluticasone propionate, Salmeterol xinafoate), Flovent (Fluticasone propionate), Serevent (Salmeterol xinafoate), Ventolin (Alberuterol sulphate) – US: Apparently tired of waiting for an FDA opinion, GSK submits drug delivery patents to FDA for Orange Book listing (FDA Law Blog)

Cinacalcet (Sensipar) – US: Teva sues Amgen for process patent infringement (Patent Docs)

Duac (Clindamycin, Benzoyl) – US: Stiefel files patent infringement suit against KV Pharmaceutical over Para IV certification concerning generic Duac (Patent Docs) (GenericsWeb)

Efexor (Venlafaxine) – Australia: Sigma seeks revocation of Wyeth’s extended release Efexor patent (GenericsWeb)

Enbrel (Etanercept) – US: CAFC deals another blow to Ariad: Amgen v Ariad Pharmaceuticals (Patent Docs)

FazaClo (Clozapine) – US: CIMA Labs files patent infringement suit against Barr following Para IV challenge (Patent Docs)

Genechip – US: E8 files patent infringement suit against Navigenics over use of GeneChip (Patent Docs)

Prandin (Repaglinide) – US: Novo Nordisk files patent infringement suit against Mylan over its ANDA to manufacture generic Prandin (Patent Docs)

Preos (Recombinant human parathyroid hormone) – Canada: Federal Court affirms likelihood of confusion between PREOS and PROTOS for osteoporosis medications: NPS Pharmaceuticals, Inc v Biofarma, Société Par Actions Simplifiée (Canadian Trademark Blog)

Protonix (Pantoprazole) – US: CAFC affirms denial of motion for preliminary injunction; motivation can prove obviousness based on structural similarity: Altana and Wyeth v Teva (Patent Baristas)

Provigil (Modfinil) – US: Apotex files suit against Cephalon seeking declaratory judgment of invalidity and non-infringement so FDA can provide Apotex with approval to market generic Provigil (Patent Docs)

Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb)

Zyprexa (Olanzapine) – Canada: Court of Appeal upholds decision that interlocutory declaratory relief is not available in a NOC proceeding: Novopharm v Eli Lilly Canada (Pharmacapsules @ Gowlings)


%d bloggers like this: